Home
Login | Register
  • Health & Wellness
  • Conditions
  • Insurance & Money
Home » Personal Health » Prescription Drugs

Eli Lilly Program To Help States Monitor Psychiatric Prescriptions Examined

All About:
  • Prescription Drugs

Submitted by Armen Hareyan on Aug 21st, 2007

A program sponsored by Eli Lilly has helped Medicaid programs in Minnesota and other states monitor prescriptions for psychiatric medications, the St. Paul Pioneer Pressreports. According to Minnesota officials, the program has helped thestate reduce costs and prevent unnecessary prescriptions forpsychiatric medications, but critics have raised concerns because thecompany has a financial interest in state policies that promote salesof such treatments (Olson, St. Paul Pioneer Press, 8/20).

Under the program, which Lilly launched in 2003, the company pays Comprehensive NeuroSciencean undisclosed amount to help state Medicaid programs monitorprescriptions for psychiatric medications. In the event that physiciansoverprescribe psychiatric medications to Medicaid beneficiaries, CNSsends "Dear Doctor" letters to inform them of the issue. Physicians donot have to comply with the letters. CNS also notifies physicians whenMedicaid beneficiaries do not renew their prescriptions for psychiatricmedications (Kaiser Daily Health Policy Report, 3/23).

Lillydoes not charge states that participate in the program. However,critics have raised concerns that "states are paying Lilly back forthis help by keeping its drugs off prior authorization lists," whichinclude medications that physicians cannot prescribe to Medicaidbeneficiaries without permission from the state, the Pioneer Press reports. None of the states that participate in the program has prior authorization lists for psychiatric medications (St. Paul Pioneer Press,8/20). Lilly manufactures Zyprexa, a treatment for schizophrenia andbipolar disorder that accounts for the single largest medicationexpenditure for state Medicaid programs (Kaiser Daily Health Policy Report, 3/23).

Lilly Response

Lilly spokesperson Janice Chavers acknowledged that the company seeksto discourage the use of prior authorization lists. She said, "We justfeel the doctor should be in the driver's seat as far as picking thebest medication, especially an antipsychotic" (St. Paul Pioneer Press, 8/20).

Reprinted with permission from kaisernetwork.org. Youcan view the entire Kaiser DailyHealth Policy Report, search the archives, and sign up for email deliveryat kaisernetwork.org/email. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, afree service of The Henry J. Kaiser Family Foundation. 2007 Advisory BoardCompany and Kaiser Family Foundation. All rights reserved.

Source: 
Kaisernetwork.org
  • Login or register to post comments

Similar Stories

  • FDA To Reduce the Misuse of Medications
  • GERD Drugs May Cause Unexpected Side Effects
  • FDA Is Not Following up on Unproven Drugs
  • FDA Approves Colcrys (Colchicine, USP) For Gout Flares Prevention
  • FDA Delays Amgen's Denosumab Osteoporosis Drug

Health Categories

 EMAXHEALTH HOME
 AFFORDABLE HEALTH INSURANCE
 DIET & WEIGHT LOSS
 FITNESS & EXERCISE
 MEN'S HEALTH
 WOMEN'S HEALTH
 BEAUTY
 ALTERNATIVE MEDICINE
 CANCER TREATMENT
 AGING
 DISEASE and CONDITION
 MENTAL HEALTH
 GENERAL HEALTH
 PERSONAL HEALTH
 GOURMET FOOD & HEALTH
 HEALING & SPIRITUALITY
 MONEY AND HEALTH

Enter email:

 Subscribe in a reader
  • Privacy Policy
  • Disclaimer
  • About Us
  • Editorial Review Process
  • Advertise
  • Contact
  • Contributors
  • Health RSS Feeds
Copyright eMaxhealth.com 2005-2009. All rights reserved.